Berenberg Bank upgraded Eli Lilly to Strong-Buy from Hold.
The bank raised its price target, implying a potential 25% upside for the stock.
Analysts expect the company to extend its obesity market leadership and exceed 2026 guidance.
The oral weight-loss treatment Foundayo has captured over 30% of new patients starting oral therapies.
Upcoming clinical data for the company’s cardiometabolic portfolio further supports this positive outlook.